Saccharomyces cerevisiae RC14

Saccharomyces cerevisiae RC14 is a specific yeast strain within the Saccharomyces cerevisiae species, characterized by its cell wall components including beta-glucans and mannoproteins that may interact with immune pattern recognition receptors. As of current available literature, strain-specific clinical data for RC14 remains unpublished, though closely related S. cerevisiae strains demonstrate measurable immunomodulatory and antimicrobial mechanisms.

Origin & History

Saccharomyces cerevisiae RC14 is a yeast strain whose specific origin and production methods are not documented in available research. Related S. cerevisiae probiotic strains like SC28-7 and CNCM I-3856 are isolated from fermentation sources such as Korean nuruk and undergo phenotypic screening for acid and bile tolerance rather than chemical extraction.

Historical & Cultural Context

No traditional medicine history exists for RC14 specifically. Related S. cerevisiae strains like SC28-7 originate from Korean nuruk fermentation starters used in alcohol brewing, selected for modern probiotic applications rather than historical therapeutic use.

Health Benefits

• No specific health benefits documented for RC14 strain - research unavailable
• Related S. cerevisiae CNCM I-3856 shows 90% reduction in Gardnerella vaginal infection load (preclinical mouse studies only)
• S. cerevisiae SC28-7 demonstrates anti-inflammatory effects reducing IL-1β and IFN-γ in colitis models (animal studies, no human trials)
• SC28-7 strain improves gut barrier function by enhancing Muc2, Muc3, ZO-1, and occludin expression (preclinical evidence only)
• CNCM I-3856 inhibits Candida hyphal genes HWP1, ECE1, SAP2, and SAP6 (in vitro and animal models, no clinical validation)

How It Works

S. cerevisiae strains generally exert effects through beta-1,3/1,6-glucans binding to Dectin-1 receptors on macrophages and dendritic cells, triggering NF-κB and CARD9 signaling pathways that modulate cytokine production including IL-6, TNF-α, and IL-10. Mannoproteins in the yeast cell wall interact with toll-like receptors (TLR2, TLR4), influencing downstream inflammatory cascades. Related strain CNCM I-3856 has been shown to competitively inhibit Gardnerella vaginalis adhesion to vaginal epithelial cells, suggesting surface-level competitive exclusion as an additional mechanism, though whether RC14 shares this property is unconfirmed.

Scientific Research

No human clinical trials, RCTs, or meta-analyses exist for Saccharomyces cerevisiae RC14. Available research consists only of preclinical studies on other S. cerevisiae strains in animal models and in vitro systems, with no PMIDs provided in the research dossier.

Clinical Summary

No published clinical trials or preclinical studies specifically investigating the RC14 strain of S. cerevisiae are currently available in peer-reviewed literature. Evidence is extrapolated from related strains: S. cerevisiae CNCM I-3856 demonstrated a 90% reduction in Gardnerella vaginalis load in preclinical mouse models, representing early-stage evidence only. S. cerevisiae SC28-7 reduced pro-inflammatory cytokines IL-1β and IFN-γ in colitis animal models, indicating anti-inflammatory potential within this species. The overall evidence base for RC14 specifically is absent, and any claimed benefits require independent strain-level validation before clinical recommendations can be made.

Nutritional Profile

Saccharomyces cerevisiae RC14 is a yeast-based probiotic strain with a nutritional composition broadly consistent with S. cerevisiae species, though strain-specific concentration data for RC14 is not independently published. General S. cerevisiae cell composition provides the following reference framework per dry weight basis: Protein: 40–50% dry weight, containing all essential amino acids including lysine (~3.5g/100g protein) and leucine (~7g/100g protein), though bioavailability is partially limited by cell wall encapsulation. B-vitamins: Thiamine (B1) ~10–15 mg/100g dry weight, Riboflavin (B2) ~4–6 mg/100g dry weight, Niacin (B3) ~30–50 mg/100g dry weight, Pyridoxine (B6) ~3–5 mg/100g dry weight, Folate ~1–2 mg/100g dry weight; B12 is absent unless fortified. Minerals: Zinc 5–10 mg/100g dry weight, Selenium variable (strain/media-dependent, typically 0.1–0.3 mg/100g in unfortified forms), Chromium ~0.1–0.2 mg/100g dry weight, Potassium ~1700–2000 mg/100g dry weight, Phosphorus ~1300–1600 mg/100g dry weight. Bioactive compounds: Beta-glucans (1,3/1,6-linked) comprising 10–15% of dry cell wall weight — known immunomodulatory activity with good oral bioactivity via Peyer's patch receptor binding (Dectin-1). Mannoproteins: 15–25% of cell wall dry weight, contribute to mucosal adhesion properties. Glutathione: ~1–3 mg/g dry weight, an endogenous antioxidant tripeptide with limited systemic bioavailability post-oral dosing. Trehalose: present intracellularly at ~5–15% dry weight depending on growth conditions, functions as a stress protectant. Ergosterol (provitamin D2 precursor): ~2–5 mg/g dry weight in standard culture; UV-activated forms can yield significant vitamin D2, but RC14-specific activation status is undocumented. Lipid content: ~4–7% dry weight, predominantly unsaturated fatty acids (oleic, palmitoleic). Fiber equivalent (cell wall polysaccharides): ~25–35% dry weight total. Bioavailability note: As a whole-cell probiotic preparation, intracellular nutrients are partially protected by the cell wall, reducing immediate bioavailability compared to lysed yeast extracts; however, cell wall components (beta-glucans, mannoproteins) are themselves bioactive and do not require cell lysis for effect. RC14 strain-specific nutritional characterization has not been published in peer-reviewed literature as of available data.

Preparation & Dosage

No clinically studied dosages exist for S. cerevisiae RC14 in any form. Related S. boulardii strains typically use 10^9 CFU/day, but RC14 lacks standardization data or human dosing studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified due to lack of RC14 research

Safety & Interactions

General S. cerevisiae supplementation is considered well-tolerated in immunocompetent adults, with the most commonly reported adverse effects being mild gastrointestinal symptoms such as bloating and flatulence. Individuals with documented yeast allergies or hypersensitivity to Saccharomyces species should avoid RC14 and related strains due to cross-reactivity risk. Immunocompromised individuals, including those on corticosteroids, calcineurin inhibitors, or biologic immunosuppressants, should avoid live yeast supplements as fungemia, though rare, has been reported with Saccharomyces supplementation in severely immunosuppressed patients. Pregnancy and lactation safety for RC14 specifically has not been established, and use during these periods should only occur under medical supervision.